Table 1. Open in new tab Demographic and...

	Outcome of Prior Treatment
Patients	44	39.3	31	27.7	37	33		112	100
Age, y, mean (SD)	47	12.1	60	8.4	51	12.0	.040	52	12.2
Sex							.258
Female	10	22.7	3	9.7	9	24.3		22	19.6
Male	34	77.3	28	90.3	28	75.7	90	80.4
Race							.056
Asian	0	0.0	3	9.7	0	0.0		3	2.7
Black	11	25.0	14	45.2	14	37.8	39	34.8
White	23	52.3	8	25.8	17	45.9	48	42.9
Other	10	22.7	6	19.4	6	16.2	22	19.6
Ethnicity: Hispanic	13	29.5	4	12.9	7	18.9	.214	24	21.4
Housing instability	21	47.7	9	29.0	14	37.8	.279	44	39.3
Comorbidities
Hepatocellular carcinoma	0	0.0	6	19.4	1	2.7	.001	7	6.3
HIV	5	11.4	4	12.9	6	16.2	.836	15	13.4
HBV	0	0.0	1	3.2	1	2.7	.517	2	1.8
Substance use
History	44	100.0	21	67.7	34	91.9	<.001	99	88.4
Active	13	29.5	6	19.4	9	24.3	.602	28	25.0
Cocaine	10	22.7	2	6.5	10	27.0	.074	22	19.6
Heroin	7	15.9	0	0.0	5	13.5	.051	12	10.7
Fentanyl	3	6.8	0	0.0	5	13.5	.101	8	7.1
Methamphetamine	1	2.3	0	0.0	1	2.7	>.99	2	1.8
Benzodiazepines	1	2.3	0	0.0	1	2.7	>.99	2	1.8
MOUD	30	68.2	7	22.6	21	56.8	.001	58	51.8
Injection drug use
History	44	100.0	31	100.0	37	100.0	>.99	89	79.5
Active	7	15.9	1	3.2	4	10.8	.268	12	10.7
Alcohol use disorder	9	20.5	6	19.4	10	27.0	.743	25	22.3
Psychiatric comorbidities
MDD	28	63.6	7	22.6	18	48.6	.002	53	47.3
Bipolar	4	9.1	1	3.2	3	8.1	.658	8	7.1
Schizophrenia	0	0.0	0	0.0	1	2.7	.607	1	0.9
PTSD	4	9.1	0	0.0	6	16.2	.058	10	8.9
GAD	3	6.8	1	3.2	0	0.0	.306	4	3.6
Cirrhosis	6	13.6	16	51.6	9	24.3	.001	31	27.7

Outcome of Prior Treatment

SVR12

Failure

Indeterminate

Total

Variable

No.

P Value

No.

Patients

39.3

27.7

112

100

Age, y, mean (SD)

12.1

8.4

12.0

.040

12.2

Sex

.258

Female

22.7

9.7

24.3

19.6

Male

77.3

90.3

75.7

80.4

Race

.056

Asian

0.0

9.7

0.0

2.7

Black

25.0

45.2

37.8

34.8

White

52.3

25.8

45.9

42.9

Other

22.7

19.4

16.2

19.6

Ethnicity: Hispanic

29.5

12.9

18.9

.214

21.4

Housing instability

47.7

29.0

37.8

.279

39.3

Comorbidities

Hepatocellular carcinoma

0.0

19.4

2.7

.001

6.3

HIV

11.4

12.9

16.2

.836

13.4

HBV

0.0

3.2

2.7

.517

1.8

Substance use

History

100.0

67.7

91.9

<.001

88.4

Active

29.5

19.4

24.3

.602

25.0

Cocaine

22.7

6.5

27.0

.074

19.6

Heroin

15.9

0.0

13.5

.051

10.7

Fentanyl

6.8

0.0

13.5

.101

7.1

Methamphetamine

2.3

0.0

2.7

>.99

1.8

Benzodiazepines

2.3

0.0

2.7

>.99

1.8

MOUD

68.2

22.6

56.8

.001

51.8

Injection drug use

History

100.0

>.99

79.5

Active

15.9

3.2

10.8

.268

10.7

Alcohol use disorder

20.5

19.4

27.0

.743

22.3

Psychiatric comorbidities

MDD

63.6

22.6

48.6

.002

47.3

Bipolar

9.1

3.2

8.1

.658

7.1

Schizophrenia

0.0

2.7

.607

0.9

PTSD

9.1

0.0

16.2

.058

8.9

GAD

6.8

3.2

0.0

.306

3.6

Cirrhosis

13.6

51.6

24.3

.001

27.7

	Outcome of Prior Treatment
Patients	44	39.3	31	27.7	37	33		112	100
Age, y, mean (SD)	47	12.1	60	8.4	51	12.0	.040	52	12.2
Sex							.258
Female	10	22.7	3	9.7	9	24.3		22	19.6
Male	34	77.3	28	90.3	28	75.7	90	80.4
Race							.056
Asian	0	0.0	3	9.7	0	0.0		3	2.7
Black	11	25.0	14	45.2	14	37.8	39	34.8
White	23	52.3	8	25.8	17	45.9	48	42.9
Other	10	22.7	6	19.4	6	16.2	22	19.6
Ethnicity: Hispanic	13	29.5	4	12.9	7	18.9	.214	24	21.4
Housing instability	21	47.7	9	29.0	14	37.8	.279	44	39.3
Comorbidities
Hepatocellular carcinoma	0	0.0	6	19.4	1	2.7	.001	7	6.3
HIV	5	11.4	4	12.9	6	16.2	.836	15	13.4
HBV	0	0.0	1	3.2	1	2.7	.517	2	1.8
Substance use
History	44	100.0	21	67.7	34	91.9	<.001	99	88.4
Active	13	29.5	6	19.4	9	24.3	.602	28	25.0
Cocaine	10	22.7	2	6.5	10	27.0	.074	22	19.6
Heroin	7	15.9	0	0.0	5	13.5	.051	12	10.7
Fentanyl	3	6.8	0	0.0	5	13.5	.101	8	7.1
Methamphetamine	1	2.3	0	0.0	1	2.7	>.99	2	1.8
Benzodiazepines	1	2.3	0	0.0	1	2.7	>.99	2	1.8
MOUD	30	68.2	7	22.6	21	56.8	.001	58	51.8
Injection drug use
History	44	100.0	31	100.0	37	100.0	>.99	89	79.5
Active	7	15.9	1	3.2	4	10.8	.268	12	10.7
Alcohol use disorder	9	20.5	6	19.4	10	27.0	.743	25	22.3
Psychiatric comorbidities
MDD	28	63.6	7	22.6	18	48.6	.002	53	47.3
Bipolar	4	9.1	1	3.2	3	8.1	.658	8	7.1
Schizophrenia	0	0.0	0	0.0	1	2.7	.607	1	0.9
PTSD	4	9.1	0	0.0	6	16.2	.058	10	8.9
GAD	3	6.8	1	3.2	0	0.0	.306	4	3.6
Cirrhosis	6	13.6	16	51.6	9	24.3	.001	31	27.7

Table 1.

Open in new tab

Demographic and Clinical Characteristics of Patients Experienced in Direct-Acting Antivirals Undergoing Retreatment, by Outcomes of Prior Treatment

	Outcome of Prior Treatment
	SVR12		Failure		Indeterminate			Total
Variable	No.	%	No.	%	No.	%	P Value	No.	%
Patients	44	39.3	31	27.7	37	33		112	100
Age, y, mean (SD)	47	12.1	60	8.4	51	12.0	.040	52	12.2
Sex							.258
Female	10	22.7	3	9.7	9	24.3		22	19.6
Male	34	77.3	28	90.3	28	75.7		90	80.4
Race							.056
Asian	0	0.0	3	9.7	0	0.0		3	2.7
Black	11	25.0	14	45.2	14	37.8		39	34.8
White	23	52.3	8	25.8	17	45.9		48	42.9
Other	10	22.7	6	19.4	6	16.2		22	19.6
Ethnicity: Hispanic	13	29.5	4	12.9	7	18.9	.214	24	21.4
Housing instability	21	47.7	9	29.0	14	37.8	.279	44	39.3
Comorbidities
Hepatocellular carcinoma	0	0.0	6	19.4	1	2.7	.001	7	6.3
HIV	5	11.4	4	12.9	6	16.2	.836	15	13.4
HBV	0	0.0	1	3.2	1	2.7	.517	2	1.8
Substance use
History	44	100.0	21	67.7	34	91.9	<.001	99	88.4
Active	13	29.5	6	19.4	9	24.3	.602	28	25.0
Cocaine	10	22.7	2	6.5	10	27.0	.074	22	19.6
Heroin	7	15.9	0	0.0	5	13.5	.051	12	10.7
Fentanyl	3	6.8	0	0.0	5	13.5	.101	8	7.1
Methamphetamine	1	2.3	0	0.0	1	2.7	>.99	2	1.8
Benzodiazepines	1	2.3	0	0.0	1	2.7	>.99	2	1.8
MOUD	30	68.2	7	22.6	21	56.8	.001	58	51.8
Injection drug use
History	44	100.0	31	100.0	37	100.0	>.99	89	79.5
Active	7	15.9	1	3.2	4	10.8	.268	12	10.7
Alcohol use disorder	9	20.5	6	19.4	10	27.0	.743	25	22.3
Psychiatric comorbidities
MDD	28	63.6	7	22.6	18	48.6	.002	53	47.3
Bipolar	4	9.1	1	3.2	3	8.1	.658	8	7.1
Schizophrenia	0	0.0	0	0.0	1	2.7	.607	1	0.9
PTSD	4	9.1	0	0.0	6	16.2	.058	10	8.9
GAD	3	6.8	1	3.2	0	0.0	.306	4	3.6
Cirrhosis	6	13.6	16	51.6	9	24.3	.001	31	27.7

	Outcome of Prior Treatment
	SVR12		Failure		Indeterminate			Total
Variable	No.	%	No.	%	No.	%	P Value	No.	%
Patients	44	39.3	31	27.7	37	33		112	100
Age, y, mean (SD)	47	12.1	60	8.4	51	12.0	.040	52	12.2
Sex							.258
Female	10	22.7	3	9.7	9	24.3		22	19.6
Male	34	77.3	28	90.3	28	75.7		90	80.4
Race							.056
Asian	0	0.0	3	9.7	0	0.0		3	2.7
Black	11	25.0	14	45.2	14	37.8		39	34.8
White	23	52.3	8	25.8	17	45.9		48	42.9
Other	10	22.7	6	19.4	6	16.2		22	19.6
Ethnicity: Hispanic	13	29.5	4	12.9	7	18.9	.214	24	21.4
Housing instability	21	47.7	9	29.0	14	37.8	.279	44	39.3
Comorbidities
Hepatocellular carcinoma	0	0.0	6	19.4	1	2.7	.001	7	6.3
HIV	5	11.4	4	12.9	6	16.2	.836	15	13.4
HBV	0	0.0	1	3.2	1	2.7	.517	2	1.8
Substance use
History	44	100.0	21	67.7	34	91.9	<.001	99	88.4
Active	13	29.5	6	19.4	9	24.3	.602	28	25.0
Cocaine	10	22.7	2	6.5	10	27.0	.074	22	19.6
Heroin	7	15.9	0	0.0	5	13.5	.051	12	10.7
Fentanyl	3	6.8	0	0.0	5	13.5	.101	8	7.1
Methamphetamine	1	2.3	0	0.0	1	2.7	>.99	2	1.8
Benzodiazepines	1	2.3	0	0.0	1	2.7	>.99	2	1.8
MOUD	30	68.2	7	22.6	21	56.8	.001	58	51.8
Injection drug use
History	44	100.0	31	100.0	37	100.0	>.99	89	79.5
Active	7	15.9	1	3.2	4	10.8	.268	12	10.7
Alcohol use disorder	9	20.5	6	19.4	10	27.0	.743	25	22.3
Psychiatric comorbidities
MDD	28	63.6	7	22.6	18	48.6	.002	53	47.3
Bipolar	4	9.1	1	3.2	3	8.1	.658	8	7.1
Schizophrenia	0	0.0	0	0.0	1	2.7	.607	1	0.9
PTSD	4	9.1	0	0.0	6	16.2	.058	10	8.9
GAD	3	6.8	1	3.2	0	0.0	.306	4	3.6
Cirrhosis	6	13.6	16	51.6	9	24.3	.001	31	27.7

Abbreviations: GAD, generalized anxiety disorder; HBV, hepatitis B virus; MDD, major depressive disorder; MOUD, medications for opioid use disorder; PTSD, posttraumatic stress disorder; SVR12, sustained virologic response at 12 weeks.

This Feature Is Available To Subscribers Only